secwatch.observer — SEC 8-K summary
======================================

Issuer:     FEMASYS INC (FEMY)
CIK:        0001339005
Form:       8-K
Filed at:   2023-11-21T23:59:59+00:00
Accession:  0001140361-23-054273
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Femasys appoints Joshua Silverman to board in connection with private placement
-------------------------------------------------------------------------------

- Joshua Silverman appointed director effective Nov 21, 2023, nominated by PharmaCyte Biotech under board nomination right.
- Silverman serves as interim CEO, President and Director of PharmaCyte Biotech.
- He is independent director under Nasdaq rules and will serve on Nominating Committee.
- Term as Class II director until annual meeting following Dec 31, 2026; entitled to standard director compensation and indemnification.
- Appointment follows previously announced private placement of convertible notes and warrants closed Nov 21, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339005/000114036123054273/0001140361-23-054273-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339005/000114036123054273/ef20015127_form8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-054273

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer